Newsroom

[Georgia Health News] Hepatitis C: The high cost of a cure

By Andy Miller May 6, 2014   Probably the biggest ethical dilemma now confronting the health care world involves two expensive new drugs to treat hepatitis […]

Read more

[The New Yorker] BIOTECH’S HARD BARGAIN

BY JAMES SUROWIECKI April 28 Issue   Few people have done better in the recent stock boom than biotech investors. Biotech was the best-performing market sector last […]

Read more

[Washington Post] An $84,000 hepatitis drug is giving states and insurers a major headache

By Jason Millman April 28, 2014   The new hepatitis C drug Sovaldi is being hailed as a potential breakthrough treatment for a disease that affects […]

Read more

[Forbes] At $1,000 A Pill, Hepatitis C Drug Sovaldi Rattles Medicaid Programs

By Bruce Jaspen April 28, 2014   Medicaid health insurance programs for the poor are grappling with how to pay for the costly Hepatitis C treatment […]

Read more